Payment overview · 2025
General Payments
$364.03
18 reported records · 10 companies
Healthcare provider profile · identity verified
Steven Allen Freeman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CORNING, IA · NPI 1497770176
Verified facts
What the public records show
CMS Open Payments records show Steven Allen Freeman, MD received $364.03 in general payments during 2025 across 18 reported records.
Vanda Pharmaceuticals Inc. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.33 | 25.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $78.32 | 21.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.45 | 13.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.88 | 11.8% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $22.85 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.04 | 4.7% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $16.54 | 4.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.82 | 4.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.30 | 4.2% | 1 | 2025 |
| LANTHEUS MEDICAL IMAGING, INC. | Unresolved — no canonical attribution shown | $13.50 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.03 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $93.33 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $61.41 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $37.85 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| DEFINITY Normalized: definity |
Drug | LANTHEUS MEDICAL IMAGING, INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 75 |
| Lisinopril | Lisinopril | 289 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 72 |
| Potassium Chloride | Potassium Chloride | 278 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 64 |
| Omeprazole | Omeprazole | 247 | 59 |
| Furosemide | Furosemide | 243 | 52 |
| Gabapentin | Gabapentin | 205 | 46 |
| Eliquis | Apixaban | 194 | 35 |
| Simvastatin | Simvastatin | 191 | 46 |
| Losartan Potassium | Losartan Potassium | 188 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 48 |
| Tramadol Hcl | Tramadol Hcl | 180 | 51 |
| Metformin Hcl | Metformin Hcl | 154 | 35 |
| Spironolactone | Spironolactone | 137 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 38 |
| Trazodone Hcl | Trazodone Hcl | 129 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 31 |
| Metformin Hcl Er | Metformin Hcl | 124 | 22 |
| Montelukast Sodium | Montelukast Sodium | 122 | 28 |
| Warfarin Sodium | Warfarin Sodium | 122 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 27 |
| Prednisone | Prednisone | 107 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 29 |
| Donepezil Hcl | Donepezil Hcl | 96 | 16 |
| Alprazolam | Alprazolam | 95 | 16 |
| Jardiance | Empagliflozin | 91 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 21 |
| Allopurinol | Allopurinol | 80 | 24 |
| Trulicity | Dulaglutide | 79 | suppressed |
| Fentanyl | Fentanyl | 74 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 17 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Ozempic | Semaglutide | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 23 |
| Meloxicam | Meloxicam | 69 | 19 |
| Glimepiride | Glimepiride | 65 | 18 |
| Carvedilol | Carvedilol | 63 | 12 |
| Lorazepam | Lorazepam | 62 | 18 |
| Glipizide | Glipizide | 61 | 12 |
| Sertraline Hcl | Sertraline Hcl | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Famotidine | Famotidine | 55 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Bumetanide | Bumetanide | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 12 |
| Celecoxib | Celecoxib | 48 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Finasteride | Finasteride | 46 | 15 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 17 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Sulfasalazine | Sulfasalazine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Acetylcysteine | Acetylcysteine | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Nateglinide | Nateglinide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 12 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Fycompa | Perampanel | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Clobazam | Clobazam | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Sulindac | Sulindac | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Linzess | Linaclotide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.03 · 18 records | Vanda Pharmaceuticals Inc. | AUSTEDO XR, Cologuard Collection Kit, DEFINITY, FANAPT, GVOKE HYPOPEN, HETLIOZ, Ozempic, QULIPTA, Rybelsus, TWIIST, TZIELD, Tresiba, UBRELVY, UZEDY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error